retained in the 96-well plate via magnetic separation using the magnetic bed. The 384-well plate was read in the Erenna system to count individual Alexa Fluor dye-labelled detection antibody molecules from each well. The limit of detection for this ET-1 assay was 0.07 pg/mL and the lower limit of quantification was 0.175 pg/mL. Intra-assay precision (20 replicates) was 3% at 11.4 pg/mL, and interassay precision (five assay runs) was 7% at 7.8 pg/mL. This assay measures the active form of ET-1. In testing to assess ET-1 sample integrity in human plasma, ET-1 showed no signal loss after 9 months of storage at −70 ∘ C. Freeze-thaw testing revealed no signal loss after seven cycles. Our samples were thawed only once previously for aliquoting from original tubes and shipping. All ET-1 measurements were performed in 2014. NT-proBNP levels were determined by the clinically available VITROS ® NT-proBNP Assay (Ortho-Clinical Diagnostics, Raritan, NJ, USA).
Clinical endpoints
The composite of death or recurrent heart failure hospitalization within 30 days of randomization was a primary endpoint in the overall ASCEND-HF trial. Death and worsening heart failure were assessed together as a composite secondary endpoint and all events were adjudicated to 180 days. In this biomarker substudy, we analysed the following adjudicated outcomes: death at 30 days; death or rehospitalization at 30 days; death at 180 days; and death or worsening heart failure prior to discharge (Supplementary material online, Table S1 ).
Statistical analyses
Baseline characteristics were presented as median [interquartile range (IQR)] for continuous variables and as a percentage for categorical variables. The Jonckheere-Terpstra and Cochran-Armitage trend tests were used to assess the significance of a trend across increasing tertiles of ET-1 for continuous and categorical variables, respectively. Two-sided P-values <0.05 were considered statistically significant. ET-1 levels were not normally distributed, and therefore were expressed as log-transformed. Baseline and follow-up ET-1 levels were compared between patients randomly assigned to placebo or nesiritide via the Wilcoxon rank sum test. The association between continuous, log-transformed ET-1 and intermediate outcomes was performed via logistic regression analyses for in-hospital death or worsening heart failure. The association between log-transformed ET-1 and long-term outcomes was performed via Cox proportional hazards models for the endpoints of 30-day mortality, 180-day mortality, in-hospital death or worsening heart failure, and 30-day mortality or rehospitalization. For multivariable analyses, hazard ratios (HRs) and odds ratios (ORs) were adjusted for covariates that were previously identified for the overall ASCEND-HF study population (ASCEND-HF risk model, Supplementary material online, Table S1 ). Age, systolic blood pressure <140 mmHg, and blood urea nitrogen (BUN) were used as covariates in multivariable analyses assessing possible associations between ET-1 and 180-day mortality. To assess if the addition of ET-1 to the ASCEND-HF risk model improves outcome prediction, we calculated the area under the receiver operating characteristic curve (AUC), integrated discrimination improvement (IDI), and category-free net reclassification improvement (NRI). NT-proBNP, cystatin C, hsCRP, and cTnI were also included as additional covariates in secondary multivariable analyses. The Kaplan-Meier method was used to compare 180-day mortality across groups. Statistical analyses were performed using R software (Version 3.1.2, Vienna, Austria). levels, correlates with clinical severity, 1,4,5 and is associated with mortality. 6 -8 Understanding changes in ET-1 during acute decompensated heart failure (ADHF) may help identify a subgroup of patients who are high risk for adverse clinical outcomes. Furthermore, it is possible that this high risk subgroup may benefit from therapies that interfere with ET-1 production or signalling, including relaxin receptor agonists. 9 In the hope of further exploring some of these possibilities, we examined the relationship of baseline and serial ET-1 measurements with mortality, worsening heart failure, and rehospitalization in hospitalized patients with ADHF who were part of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) biomarker substudy. In this observational, hypothesis-generating analysis, we also assessed ET-1's potential prognostic role in relation to acute heart failure biomarkers, including NT-proBNP.
Methods

Study population
The ASCEND-HF trial was a multicentre randomized double-blind placebo-controlled trial that evaluated the effects of nesiritide, a recombinant BNP and vasodilator, in patients hospitalized with ADHF. We excluded patients with clinical evidence of acute coronary syndrome or baseline cardiac troponin >5 times the upper reference limit, as measured by the local clinical laboratory. The design and primary results of ASCEND-HF have been previously reported. 10,11 Studies assessing cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hsCRP), and cystatin C in acute heart failure using subcohorts from ASCEND-HF have been previously published. 12 -14 Out of 7411 patients randomized in ASCEND-HF, our biomarker study enrolled 872 patients in whom ET-1 was measured from serial venous blood sampling at baseline, 48-72 h after therapy initiation, and at a 30-day follow-up visit. Blood samples were collected in EDTA-plasma between June 2008 and September 2010. They were immediately centrifuged and stored at −80 ∘ C for subsequent analysis at a core laboratory.
Endothelin-1 measurement
Circulating plasma ET-1 levels were measured from plasma samples taken at baseline (n = 872), 48-72 h (n = 691), and 30 days (n = 643). Measurements were performed using the Erenna ® Immunoassay Sys-tem (Singulex, Inc., Alameda, CA, USA), which is based upon single molecule counting technology. 15 Specifically, 100 L of assay buffer with paramagnetic microparticles (1 μm, Dynabeads ® MyOne™, Life Technologies) coated with capture antibody (MAB3440, R&D Systems, Minneapolis, MN, USA) were added to each well in a 96-well plate; 100 L assay samples were added to each well in the plate. The plate was covered and incubated for 2 h at 25 ∘ C. The plate was then washed to remove unbound material, and a magnetic bed (Ambion) was used to retain the microparticles in the well. Then, 20 L of detection antibody (MA3005, R&D Systems) with Alexa Fluor ® label were added to each well. The plate was covered and incubated for 1 hat25 ∘ Cand washed. The magnetic bed was used to retain microparticles in the well, and was transferred to a fresh 96-well plate, and the bound detection antibody was released from the microparticles via elution with 10 L of glycine. Glycine buffer, containing Alexa Fluor dye-labelled detection antibody (MA3005, R&D Systems), was transferred to a 384-well receptacle plate containing 10 L of 0.5 M Tris buffer. The microparticles were
